Hospital Arnau de Vilanova de Valencia

Valencia 46015

1 studies enrolling now · 4 studies all time

What they study most

Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-positive Breast Cancer, HIV-1-infection, Residual Invasive Breast Cancer

Studies at this site

• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer — Running, not enrolling
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated — Stopped early